0001562180-18-004218.txt : 20181015 0001562180-18-004218.hdr.sgml : 20181015 20181015175419 ACCESSION NUMBER: 0001562180-18-004218 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181011 FILED AS OF DATE: 20181015 DATE AS OF CHANGE: 20181015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Velleca Mark A. CENTRAL INDEX KEY: 0001706847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 181123211 MAIL ADDRESS: STREET 1: 79 TW ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 79 T.W. ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: P. O. BOX # 110341 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-10-11 false 0001560241 G1 Therapeutics, Inc. GTHX 0001706847 Velleca Mark A. C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR. 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 true true false false President and CEO Common Stock 2018-10-11 4 M false 10000.00 0.39 A 19000.00 D Common Stock 2018-10-15 4 M false 5000.00 3.72 A 24000.00 D Common Stock 2018-10-15 4 S false 2163.00 40.9009 D 21837.00 D Common Stock 2018-10-15 4 S false 2837.00 42.008 D 19000.00 D Stock Options (Right to Buy) 0.39 2018-10-11 4 M false 10000.00 0.00 D 2024-05-09 Common Stock 10000.00 389286.00 D Stock Options (Right to Buy) 3.72 2018-10-15 4 M false 5000.00 0.00 D 2025-12-21 Common Stock 5000.00 124433.00 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The price represents the weighted average price with a low of $40.60 and a high of $41.10. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 and 3 to this Form 4. The price represents the weighted average price with a low of $41.95 and a high of $42.29. All shares underlying this option have vested. The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. /s/ James Stillman Hanson, attorney-in-fact 2018-10-15